Key facts
- What it is: LL-37 is the only human cathelicidin antimicrobial peptide.
- Evidence: Extensive biology, limited therapeutic translation.
- Status: Endogenous antimicrobial peptide; no approved LL-37 therapy.
- Main caution: Potential concerns include local cytotoxicity, unwanted immune activation, and disease-specific inflammatory effects.
- Sources: 5 PubMed-indexed papers linked below.
What is LL-37?
LL-37 is the only human cathelicidin antimicrobial peptide. Epithelial cells and immune cells produce it as part of innate defense. It can kill microbes, recruit immune cells, alter inflammation, and affect wound biology. Those multiple roles make it a research target—not an automatically safe antimicrobial supplement.
The first SEO trap with peptide content is treating every compound as if it belongs to the same category. It does not. Some peptides are approved prescription medicines supported by randomized trials; others are endogenous signaling molecules being studied in cells; others are unapproved chemicals sold with no regulated manufacturing chain. For LL-37, the evidence and regulatory category above determine what conclusions are reasonable.
This guide does not provide a dose, cycle, protocol, source, or personal recommendation. It translates published research so readers can distinguish a measured result from a marketing claim and bring better questions to a licensed clinician.
How does LL-37 work?
Its cationic amphipathic structure can disrupt microbial membranes. LL-37 also signals through host receptors, influences chemotaxis, binds nucleic acids, and can amplify or restrain inflammation depending on context. The same biology that supports defense can contribute to inflammatory disease.
Mechanism is not the same as clinical benefit. A compound can activate a receptor, change a biomarker, or improve an animal model without improving how people feel, function, or survive. The strongest medical claims require controlled human outcomes, not a plausible pathway alone.
What does the research on LL-37 show?
Human observational studies link deficient skin antimicrobial activity with atopic dermatitis, while laboratory and animal work shows protection against invasive infection. Research also implicates LL-37 in autoimmune and inflammatory pathways. Direct therapeutic trials remain limited relative to the breadth of mechanistic literature.
These papers were selected to show the shape of the evidence: foundational biology, clinical trials where they exist, safety signals, and reviews that place single studies in context. A citation does not mean PepMate endorses a treatment; it lets readers inspect the original record.
How strong is the evidence?
Evidence assessment: Extensive biology, limited therapeutic translation. Endogenous association does not show that adding synthetic LL-37 improves outcomes. Stability, delivery, tissue toxicity, and context-dependent inflammation are major translational barriers.
Evidence strength depends on study design, directness, replication, sample size, and whether researchers measured a meaningful outcome. Animal evidence can justify a human trial, but it cannot establish a human treatment. Observational human data can identify associations, but it cannot reliably prove cause and effect.
Is LL-37 approved or available?
Endogenous antimicrobial peptide; no approved LL-37 therapy. Approval is tied to a specific product, indication, population, formulation, and regulator. “Research use only,” clinic availability, compounding, or a listing on a peptide website is not the same as approval. Availability can change, so current regulator labeling and professional guidance take priority over any static article.
LL-37 safety, risks, and evidence gaps
Potential concerns include local cytotoxicity, unwanted immune activation, and disease-specific inflammatory effects. There is no standardized approved product for self-treatment.
Endogenous association does not show that adding synthetic LL-37 improves outcomes. Stability, delivery, tissue toxicity, and context-dependent inflammation are major translational barriers.
Unapproved online peptides add risks that a paper about a verified laboratory compound cannot measure: mislabeling, contamination, sterility failure, degradation, and a concentration different from the label. Even an endogenous or short peptide can cause harm when the route, exposure, or manufacturing quality changes.
Frequently asked questions
What is LL-37?
LL-37 is the only human cathelicidin antimicrobial peptide. Epithelial cells and immune cells produce it as part of innate defense. It can kill microbes, recruit immune cells, alter inflammation, and affect wound biology. Those multiple roles make it a research target—not an automatically safe antimicrobial supplement.
How does LL-37 work?
Its cationic amphipathic structure can disrupt microbial membranes. LL-37 also signals through host receptors, influences chemotaxis, binds nucleic acids, and can amplify or restrain inflammation depending on context. The same biology that supports defense can contribute to inflammatory disease.
Is LL-37 FDA-approved?
Endogenous antimicrobial peptide; no approved LL-37 therapy. Approval is indication-specific and can differ by country; check current regulator labeling rather than relying on peptide-shop descriptions.
What does PubMed research on LL-37 show?
Human observational studies link deficient skin antimicrobial activity with atopic dermatitis, while laboratory and animal work shows protection against invasive infection. Research also implicates LL-37 in autoimmune and inflammatory pathways. Direct therapeutic trials remain limited relative to the breadth of mechanistic literature.
What are the main risks of LL-37?
Potential concerns include local cytotoxicity, unwanted immune activation, and disease-specific inflammatory effects. There is no standardized approved product for self-treatment.
PubMed sources
Every medical claim in this guide is anchored to peer-reviewed or scholarly literature indexed on PubMed. Open the abstracts below to review the study design, population, and limitations.
- LL-37, the only human member of the cathelicidin family of antimicrobial peptides. — PubMed 16716248 (2006)
- LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunity. — PubMed 39643165 (2025)
- Endogenous antimicrobial peptides and skin infections in atopic dermatitis. — PubMed 12374875 (2002)
- Innate antimicrobial peptide protects the skin from invasive bacterial infection. — PubMed 11719807 (2001)
- LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. — PubMed 11015447 (2000)
Source selection and update method: PepMate Research Editorial Policy. Last updated 22 July 2026.